Ketorolac Aurobindo (Ketorolac Trometamol)

Ketorolac Trometamol works by non‑selectively blocking the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which reduces the synthesis of prostaglandins. Lower prostaglandin levels diminish inflammation and interrupt pain signaling pathways, resulting in effective analgesia and anti‑inflammatory effects.

The specific dose and duration of Ketorolac Aurobindo are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and overall risk profile. Healthcare professionals follow local guidelines and product labeling to set an appropriate regimen.

Safety data for Ketorolac Trometamol in pregnancy are limited, and the drug is generally avoided in the third trimester because of potential fetal renal toxicity. Use during pregnancy or lactation should only occur if the prescriber judges that the benefit outweighs the risk, and close monitoring is advised.

To request Ketorolac Aurobindo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Ketorolac Aurobindo offers potent analgesia comparable to moderate‑dose opioids but without the risk of respiratory depression. Compared with other NSAIDs such as ibuprofen, it has a faster onset and stronger effect, making it suitable for short‑term, severe pain. However, it carries higher risks of renal and gastrointestinal adverse events, requiring careful patient selection.

The injectable solution should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use, and discard any vial that shows particulate matter or discoloration.

Ketorolac Aurobindo is administered by a healthcare professional via intramuscular or intravenous injection. The route, site, and rate of administration are selected by the prescriber based on the clinical situation and patient characteristics.

The most serious risks include gastrointestinal bleeding or perforation, acute renal failure, cardiovascular events such as myocardial infarction or stroke, and severe hypersensitivity reactions including anaphylaxis. Patients should be monitored closely for signs of bleeding, reduced urine output, chest pain, or rash.

Ketorolac Aurobindo is contraindicated in patients with known hypersensitivity to ketorolac or other NSAIDs, active gastrointestinal ulceration or bleeding, severe renal impairment, advanced heart failure, and in the third trimester of pregnancy. It should also be avoided in individuals receiving certain anticoagulants or other NSAIDs without medical supervision.